Nephrology Dialysis Transplantation

Journal Information
ISSN / EISSN : 09310509 / 14602385
Current Publisher: Oxford University Press (OUP) (10.1093)
Total articles ≅ 29,781
Google Scholar h5-index: 66
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
LOCKSS
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Anique D Ter Braake, Coby Eelderink, Lara W Zeper, Andreas Pasch, Stephan J L Bakker, Martin H De Borst, Joost G J Hoenderop, Jeroen H F De Baaij
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz190

Abstract:Background Phosphate (Pi) toxicity is a strong determinant of vascular calcification development in chronic kidney disease (CKD). Magnesium (Mg2+) may improve cardiovascular risk via vascular calcification. The mechanism by which Mg2+ counteracts vascular calcification remains incompletely described. Here we investigated the effects of Mg2+ on Pi and secondary crystalline calciprotein particles (CPP2)-induced calcification and crystal maturation. Methods Vascular smooth muscle cells (VSMCs) were treated with high Pi or CPP2 and supplemented with Mg2+ to study cellular calcification. The effect of Mg2+ on CPP maturation, morphology and composition was studied by medium absorbance, electron microscopy and energy dispersive spectroscopy. To translate our findings to CKD patients, the effects of Mg2+ on calcification propensity (T50) were measured in sera from CKD patients and healthy controls. Results Mg2+ supplementation prevented Pi-induced calcification in VSMCs. Mg2+ dose-dependently delayed the maturation of primary CPP1 to CPP2 in vitro. Mg2+ did not prevent calcification and associated gene and protein expression when added to already formed CPP2. Confirmatory experiments in human serum demonstrated that the addition of 0.2 mmol/L Mg2+ increased T50 from healthy controls by 51 ± 15 min (P < 0.05) and CKD patients by 44 ± 13 min (P < 0.05). Each further 0.2 mmol/L addition of Mg2+ led to further increases in both groups. Conclusions Our results demonstrate that crystalline CPP2 mediates Pi-induced calcification in VSMCs. In vitro, Mg2+ delays crystalline CPP2 formation and thereby prevents Pi-induced calcification.
Manliu Wang, Jicheng Lv, Pei Chen, Guizhen Yu, Sufang Shi, Lijun Liu, Xujie Zhou, Damin Xu, Minghui Zhao, Hong Zhang
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz171

The publisher has not yet granted permission to display this abstract.
Kate A Robinson, Luke A Baker, Matthew P M Graham-Brown, Emma L Watson
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz193

The publisher has not yet granted permission to display this abstract.
Yu Ho Lee, Ki Pyo Kim, Sun-Hwa Park, Dong-Jin Kim, Yang-Gyun Kim, Ju-Young Moon, Su-Woong Jung, Jin Sug Kim, Kyung-Hwan Jeong, So-Young Lee, et al.
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz168

The publisher has not yet granted permission to display this abstract.
Takamasa Iwakura, Julian A Marschner, Zhi Bo Zhao, Monika Katarzyna Świderska, Hans-Joachim Anders
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz191

The publisher has not yet granted permission to display this abstract.
Carmine Zoccali, Peter J Blankestijn, Annette Bruchfeld, Giovambattista Capasso, Danilo Fliser, Denis Fouque, Dimitrios Goumenos, Ziad Massy, Ivan Rychlık, Maria J Soler, et al.
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz199

The publisher has not yet granted permission to display this abstract.
Manon J M Van Oosten, Susan J J Logtenberg, Martijn J H Leegte, Henk J G Bilo, Sigrid M Mohnen, Leona Hakkaart-Van Roijen, Marc H Hemmelder, G Ardine De Wit, Kitty J Jager, Vianda S Stel
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz146

Abstract:Background The financial burden of chronic kidney disease (CKD) is increasing due to the ageing population and increased prevalence of comorbid diseases. Our aim was to evaluate age-related differences in health care use and costs in Stage G4/G5 CKD without renal replacement therapy (RRT), dialysis and kidney transplant patients and compare them to the general population. Methods Using Dutch health care claims, we identified CKD patients and divided them into three groups: CKD Stage G4/G5 without RRT, dialysis and kidney transplantation. We matched them with two controls per patient. Total health care costs and hospital costs unrelated to CKD treatment are presented in four age categories (19–44, 45–64, 65–74 and ≥75 years). Results Overall, health care costs of CKD patients ≥75 years of age were lower than costs of patients 65–74 years of age. In dialysis patients, costs were highest in patients 45–64 years of age. Since costs of controls increased gradually with age, the cost ratio of patients versus controls was highest in young patients (19–44 years). CKD patients were in greater need of additional specialist care than the general population, which was already evident in young patients. Conclusion Already at a young age and in the earlier stages of CKD, patients are in need of additional care with corresponding health care costs far exceeding those of the general population. In contrast to the general population, the oldest patients (≥75 years) of all CKD patient groups have lower costs than patients 65–74 years of age, which is largely explained by lower hospital and medication costs.
Louise Oni
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz184

Rute B Baptista, Edgar Almeida
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz197